CLINICAL ROLE -
Current Drug Pathways in Non–Small Cell Lung Cancer
Advancements in genomic and mutational analysis show that up to 60% of adenocarcinomas and up to 50% to 80% of squamous cell carcinomas (SCC) have a known oncogenic driver mutation.
Read More